Alternative Research Initiative (ARI) works to provide researched-based solutions in a variety of social fields, including health, education, governance, culture, etc. in Pakistan. Though a new name in Pakistan's consulting sector, ARI is known for its quality research and monitoring and evaluation services.
Established in 2017, ARI offers analytical research and outreach services, identifying and analyzing social issues, in order to provide long-term practical innovative solutions, both for public and private sectors.
ARI has a strong internal team comprising researchers, policy analysts, writers, monitoring and evaluation experts and IT experts. Additionally ARI has a vast pool of experts from the fields of health, harm reduction, economy, governance, parliamentary strengthening, culture, etc.
Over the last two years, ARI has conducted countrywide surveys and research studies on various issues of health.
Imagine the outrage if an international non-governmental organization (NGO) focusing on drug abuse called for naloxone manufacturers to not sell their products in low- and middle-income countries (LMICs) on grounds that it would confuse regulators and the public, suggesting instead that they focus on ending opioid abuse using only regulatory and educational approaches? How would NGOs in these countries react if this international NGO went further and called on governments to ban the use of naloxone? Recall that naloxone is about 85-95% effective in preventing death from an opioid overdose. Read More
On April 16, the Global State of Tobacco Harm Reduction (GSTHR) released its newest report-"Tobacco Harm Reduction: A Burning Issue for Asia"-detailing how countries in the region have largely failed to consider safer nicotine products (SNPs) to combat the smoking-related death toll.
Imagine the outrage if an international non-governmental organization (NGO) focusing on drug abuse called for naloxone manufacturers to not sell their products in low- and middle-income countries (LMICs) on grounds that it would confuse regulators and the public, suggesting instead that they focus on ending opioid abuse using only regulatory and educational approaches? How would NGOs in these countries react if this international NGO went further and called on governments to ban the use of naloxone? Recall that naloxone is about 85-95% effective in preventing death from an opioid overdose.
In his new book, Good Business: The Talk, Fight, Win Way to Change the World, Bill Novelli describes, among other things, opportunities that may arise from working with a cancelled industry. Ultimately, however, Novelli's inconsistency on this stance reveals the power of cancel culture to stifle dialogue and impede clearheaded action.
In the United States, menthol cigarettes rose to popularity during the 1950s. At about the same time, manufacturers began focusing their marketing efforts on Black Americans. The effects of these campaigns can be felt today, with Black smokers making up more than one quarter of all menthol users in the United States.
In 2020, The International Union Against Tuberculosis and Lung Disease (The Union), a Bloomberg partner for 'The Initiative to reduce tobacco use', published its fourth position statement on e-cigarettes. In it, The Union called for a blanket ban on all electronic nicotine delivery systems (ENDS) and heated tobacco products (HTPs) in low- and middle-income countries (LMICs).
One of the targets of Sustainable Development Goal 3 is to "strengthen the implementation of the World Health Organization Framework Convention on Tobacco Control (FCTC) in all countries, as appropriate." The indicator for measuring the implementation of FCTC is "age-standardized prevalence of current tobacco use among persons aged 15 years and older."
Under the new proposals, nicotine-containing vaping products would be required to carry a warning label pointing out their addiction potential in both English and te reo Maori, similar to the ones found on cigarettes.
Beamsville, ON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- For the better part of the last decade, advocates have fought for vaping to be recognised as a harm reduction tool for adult smokers. In the time since, science has caught up with the industry's message and vaping has been recognized by all health organizations as far less harmful than smoking. Yet, despite the overwhelming evidence concluding that vaping is less harmful, smokers and society at large are still being sent mixed messages by the government and misleading information by media to support a sensationalistic narrative.
In Part I, I discussed failures in the implementation of the Global Strategy to Accelerate Tobacco Control 2019-2025 (GS2025). As that post indicates, there are many factors contributing to shortcomings on this front. In the current piece, I focus on one where a country, Thailand, which, in my opinion, is still facing challenges in reducing smoking rates despite putting in place policies as outlined in GS2025.
For decades, the US was a leader in global health. It played a key role in establishing the World Health Organization (WHO), steered the eradication of diseases like smallpox, and guided the development of innumerable standards that underpin modern health policy. Then came the Trump Presidency. Over the past four years, and particularly throughout the COVID-19 pandemic, the administration repeatedly failed to embrace sound health policy, to disastrous effect. The election of Joe Biden must bring about a reversal of these failures.
Perspectives regarding the Report on the Tenth Meeting of the WHO Study Group on Tobacco Product Regulation to be considered at the 148th session of the Executive Board of the World Health Organization.
It was an era in which we became accustomed to daily death tolls broadcast on TV; work, school, and play shifted to virtual space; and masks served as both a life-saving accessory and confounding controversy. On many fronts, the era was marked by despair, not only from the virus proper, but also from the isolation.
In 2018, the World Health Organization (WHO) adopted the Global Strategy to Accelerate Tobacco Control 2019-2025 (GS2025). Described as "a blueprint for the global tobacco control community," this strategy sought to accelerate implementation of the WHO Framework Convention on Tobacco Control (FCTC). Two years later, one cannot help but notice the absence of any report on progress toward this goal-an absence that was made all the more glaring when the WHO relaunched GS2025 last month. Intended to coincide with what would have been the Ninth Session of the Conference of the Parties to the FCTC (COP9), this relaunch only highlighted ongoing failures in policy implementation.
Early in 1987 the Conservative government took the radical decision to provide sterile injecting equipment to people who inject in response to the HIV crisis. Only a few months before, it had run an anti-heroin campaign. Now it was giving out free syringes.
I recently addressed the 2020 GTNF conference on the topic of "who is getting tobacco regulation right?". My answer was blunt: at present, very few! If we were, we would not have eight million deaths a year from tobacco use. Nor would we have 1.3 billion people still using tobacco products, most in a toxic combustible or dangerous smokeless form. The goal of a regulator should be primarily to reduce that harm in the fastest possible time. Sadly, this isn't the case today.
The focus of this report is on the contradictions and conflicts experienced by governments that own major stakes in tobacco companies, yet are required to support tobacco control at the same time because they are signatories to the World Health Organization's Framework Convention on Tobacco Control (FCTC). The broader tobacco control environment is not covered by the report, although the context is important.
As a result of the COVID-19 pandemic, it is a challenge for the scientific community to publish results quickly, and publication often occurs at the price of quality and reproducibility, which in turn undermines the public's trust of science.
ENDS are considerably less harmful than cigarettes. Imposing the same tax burden on them (per unit of "harm") as on cigarettes leads to poorer health outcomes. Differential tax treatment of ENDS will encourage more cigarette smokers to switch to ENDS and could save millions of lives worldwide.
Major gaps remain in cessation products' availability and resource allocation for cessation services globally. Current licensed products are falling short on delivering and sustaining smoking cessation. Innovation in cessation products and services needs to build on learnings in nicotine pharmacokinetics, behavioural insights from consumer research and tap into 21st century tools such as mobile based apps. National implementation of FCTC's Article 14 needs to follow guidelines that encourage integration into existing health programmes and health-care practitioners' (HCPs) upskilling.
This study specifically assessed public perceptions of nicotine as opposed to products containing nicotine, which is the focus of previous studies. Apart from showing that consumers often incorrectly perceive nicotine and cigarettes as similar in terms of harmfulness, the authors highlight the need for more accurate and complete reporting by the media to clarify widespread misunderstandings and mitigate public uncertainty.
The purpose of this paper is to illustrate the opportunities for tobacco farmers in Malawi from diversifying to cannabis, and the potential benefits for reducing deforestation by producing a cannabis based alternative fuel. It further argues that there are tensions between the conflicting objectives of the Framework Convention on Tobacco Control and the Single Convention on Narcotic Drugs.
This paper aims to investigate the extent to which three subgroups - people with mental health conditions, people belonging to sexual minority and gender groups and Indigenous peoples - have been "left behind" by countries implementing the World Health Organization's Framework Convention on Tobacco Control
Toxicological testing, population studies, clinical trials and randomized controlled trials demonstrate the potential reductions in exposures for smokers. Many barriers impede the implementation of product substitution in tobacco harm reduction. These products have been subjected to regulatory bans and heavy taxation and are rejected by smokers and society based on misperceptions about nicotine, sensational media headlines and unsubstantiated fears of youth addiction. These barriers will need to be addressed if tobacco harm reduction is to make the maximum impact on the tobacco endemic.
Despite the FCTC detailing the significance of the research, studies are still lacking in the Global South. There are significant research gaps such as longitudinal studies, harm reduction and randomized controlled trials.
For more than thirty years, there have been many calls for the mainstreaming of gender into tobacco control; however, insufficient progress has been made with dire health and economic consequences.
The new generation of tobacco harm reduction products (HRPs) has the potential to save millions of lives and finally end the use of toxic combustible cigarettes.
Smoking-related mortality in 2060 could be cut by about 3.5 million deaths if we: (1) increase access to THR products; and (2) improve treatment, cessation, and diagnostic tools.
Ex-smokers deserve a seat at the table in decisions affecting not only names, but research priorities, regulations, taxes, and bans that affect them.
"Two research studies have highlighted the effective role tobacco harm reduction and cessation strategies can play in achieving the objectives of FCTC and reducing combustible smoking," said Arshad Ali Syed, Project Director of PANTHR. Smoking cessation is completely missing from the tobacco control efforts in Pakistan, he added.
Current available cessation products and services are suboptimal in their effectiveness. Cost and efficacy of current smoking cessation medications on the market is an impediment to availability, accessibility and cessation success in Low-Middle Income Countries (LMICs).
As we evaluate progress toward the goals of the FCTC and how best to update its text, it is vital that we learn from the challenges of other treaties, as well as shortcomings of the FCTC itself. Future efforts must prioritize the end of adult smoking, with particular emphasis on demographics and regions where progress has been slow.
Smokers have never been part of the tobacco control policies in Pakistan. Around 27% smokers in Pakistan at least make one attempt in a year and out of them 2.8% quit smoking successfully.
THC and nicotine vaping involve different devices, liquids, supply chains, people, and purposes. They should not be confused. But they were. Our analysis shows that evaluated news coverage focused primarily on nicotine vaping, and on nicotine itself.
Pakistan is a country with heavy use of tobacco. With more than 24 million...
KAP Study: This study explores the knowledge, attitude, and practices...
The Birth of Harm Reduction Informs the World's Need for Safer Nicotine...
Alternative Research Initiative (ARI) works to provide researched-based solutions...
All rights reserved. © ARI 2020